objective: to evaluate the impact of luteal phase support with vaginal progesterone on pregnancy rates in the intrauterine insemination (iui) cycles, stimulated with clomiphene citrate and human menopausal gonadotropin (hmg), in sub fertile couples. materials and methods: this prospective, randomized, double blind study was performed in a tertiary infertility center from march 2011 to january 2...

PCNA reactivity was estimated for the luminal and glandular epithelium and for the stromal cells. Treatment of clomiphene citrate decreased the proliferation of the luminal epithelial cell and stromal cells to the same extent as ovariectomy. In both of these groups, the proportion of anti–PCNA positive cells in the glandular epithelium was significantly higher than in the luminal epihelium and ...

Clomiphene citrate is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix. It may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomiphene citrate initiates a series of endocrine events culminating in a preovulatory gonadotropin...

Clomiphene citrate is a white to pale yellow, essentially odorless, crystalline powder. It is freely soluble in methanol; soluble in ethanol; slightly soluble in acetone, water, and chloroform; and insoluble in ether. CLOMID is a mixture of two geometric isomers [cis (zuclomiphene) and trans (enclomiphene)] containing between 30% and 50% of the cis-isomer. Each white scored tablet contains 50 m...